Zobrazeno 1 - 10
of 89
pro vyhledávání: '"Tadahiko Igarashi"'
Autor:
Yuji Okamoto, Mitsuhito Hirano, Kai Morino, Masashi K. Kajita, Shinji Nakaoka, Mayuko Tsuda, Kei-ji Sugimoto, Shigehisa Tamaki, Junichi Hisatake, Hisayuki Yokoyama, Tadahiko Igarashi, Atsushi Shinagawa, Takeaki Sugawara, Satoru Hara, Kazuhisa Fujikawa, Seiichi Shimizu, Toshiaki Yujiri, Hisashi Wakita, Kaichi Nishiwaki, Arinobu Tojo, Kazuyuki Aihara
Publikováno v:
npj Systems Biology and Applications, Vol 8, Iss 1, Pp 1-10 (2022)
Abstract Chronic myeloid leukemia (CML) is a myeloproliferative disorder caused by the BCR-ABL1 tyrosine kinase. Although ABL1-specific tyrosine kinase inhibitors (TKIs) including nilotinib have dramatically improved the prognosis of patients with CM
Externí odkaz:
https://doaj.org/article/58f4e055c3eb45ed81510406b1170155
Autor:
Kaichi Nishiwaki, Kei‐ji Sugimoto, Shigehisa Tamaki, Junichi Hisatake, Hisayuki Yokoyama, Tadahiko Igarashi, Atsushi Shinagawa, Takeaki Sugawara, Satoru Hara, Kazuhisa Fujikawa, Seiichi Shimizu, Toshiaki Yujiri, Arinobu Tojo, Hisashi Wakita
Publikováno v:
Cancer Medicine, Vol 9, Iss 11, Pp 3742-3751 (2020)
Abstract For patients who have chronic myeloid leukemia (CML), one of the primary treatment options is administration of nilotinib 300 mg twice daily (BID). In previous studies which compared outcomes associated with nilotinib or imatinib treatment,
Externí odkaz:
https://doaj.org/article/d6cec3dbf9054fe0b643aba4e9c79cd9
Autor:
Kana Miyazaki, Naoko Asano, Tomomi Yamada, Kohta Miyawaki, Rika Sakai, Tadahiko Igarashi, Momoko Nishikori, Kinya Ohata, Kazutaka Sunami, Isao Yoshida, Go Yamamoto, Naoki Takahashi, Masataka Okamoto, Hiroki Yano, Yuki Nishimura, Satoshi Tamaru, Masakatsu Nishikawa, Koji Izutsu, Tomohiro Kinoshita, Junji Suzumiya, Koichi Ohshima, Koji Kato, Naoyuki Katayama, Motoko Yamaguchi
Publikováno v:
Haematologica, Vol 105, Iss 9 (2019)
CD5-positive diffuse large B-cell lymphoma (CD5+ DLBCL) is characterized by poor prognosis and a high frequency of central nervous system relapse after standard immunochemotherapy. We conducted a phase II study to investigate the efficacy and safety
Externí odkaz:
https://doaj.org/article/fb4a8a0c48274a3cb4d5415fe6b4cc4b
Autor:
Tomohiro Aoki, Koji Izutsu, Ritsuro Suzuki, Chiaki Nakaseko, Hiroshi Arima, Kazuyuki Shimada, Akihiro Tomita, Makoto Sasaki, Jun Takizawa, Kinuko Mitani, Tadahiko Igarashi, Yoshinobu Maeda, Noriko Fukuhara, Fumihiro Ishida, Nozomi Niitsu, Ken Ohmachi, Hirotaka Takasaki, Naoya Nakamura, Tomohiro Kinoshita, Shigeo Nakamura, Michinori Ogura
Publikováno v:
Haematologica, Vol 99, Iss 12 (2014)
The prognosis of patients with primary mediastinal large B-cell lymphoma has improved over recent years. However, the optimal treatment strategy including the role of radiotherapy remains unknown. We retrospectively analyzed the clinical outcomes of
Externí odkaz:
https://doaj.org/article/b514f320357e478487d2ef3ca3592544
Autor:
Koji Kato, Kiyoshi Ando, Yasuhito Terui, Tadahiko Igarashi, Dai Maruyama, Hidetsugu Kawai, Eiji Kiyohara, Kenya Nakai, Toshiki Uchida, Tomomitsu Miyagaki, Kensei Tobinai, Mamiko Sakata-Yanagimoto, Junya Kuroda, Yoshiki Tokura, Noriko Fukuhara, Jiro Fujita, Takayuki Ishikawa, Kentaro Yonekura, Tadashi Nakanishi, Kazuhito Yamamoto, Risa Matsunaga
Publikováno v:
Cancer Science
E7777 is a recombinant cytotoxic fusion protein composed of the diphtheria toxin fragments A and B and human interleukin‐2. It shares an amino acid sequence with denileukin diftitox, but has improved purity and an increased percentage of active mon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0cac3fb385165954f4b66357a15dbc43
https://doi.org/10.1111/cas.14906
https://doi.org/10.1111/cas.14906
Autor:
Yoko Inaguma, Eiichi Ohtsuka, Yukiyoshi Moriuchi, Kazuho Miyashita, Masashi Mizokami, Nobuhiko Yamauchi, Tadahiko Igarashi, Koji Izutsu, Hiroshi Gomyo, Nobuko Kubota, Ryuzo Ueda, Mio Kurata, Yoshiko Inoue, Yoshiko Atsuta, Rika Sakai, Norifumi Tsukamoto, Yoko Ushijima, Kisato Nosaka, Dai Maruyama, Sachiko Suzuki, Toshiki Uchida, Shinichiro Yoshida, Ilseung Choi, Shigeru Kusumoto, Go Yamamoto, Yasuhito Tanaka, Kensuke Kojima, Satoshi Ichikawa, Hideki Tsujimura
Publikováno v:
Cancer Science
We conducted a nationwide retrospective analysis of 116 hepatitis B virus (HBV) surface antigen (HBsAg)‐positive patients with diffuse large B‐cell lymphoma (DLBCL) and 278 HBsAg‐negative patients with DLBCL, as a control cohort, who received r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0370dd68fe776aae56a8d763104043af
https://doi.org/10.1111/cas.14846
https://doi.org/10.1111/cas.14846
Autor:
Kohta Miyawaki, Koji Kato, Naoyuki Katayama, Isao Yoshida, Satoshi Tamaru, Kazutaka Sunami, Kinya Ohata, Go Yamamoto, Tadahiko Igarashi, Koji Izutsu, Masakatsu Nishikawa, Naoko Asano, Masataka Okamoto, Junji Suzumiya, Koichi Ohshima, Hiroki Yano, Kana Miyazaki, Yuki Nishimura, Motoko Yamaguchi, Tomohiro Kinoshita, Tomomi Yamada, Momoko Nishikori, Rika Sakai, Naoki Takahashi
Publikováno v:
Haematologica
CD5-positive diffuse large B-cell lymphoma (CD5+ DLBCL) is characterized by poor prognosis and a high frequency of central nervous system relapse after standard immunochemotherapy. We conducted a phase II study to investigate the efficacy and safety
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac74ee81811952309bd4095d7eb3d71d
https://doi.org/10.3324/haematol.2019.231076
https://doi.org/10.3324/haematol.2019.231076
Autor:
Junichi Hisatake, Takeaki Sugawara, Shigehisa Tamaki, Kaichi Nishiwaki, Kazuhisa Fujikawa, Hisashi Wakita, Toshiaki Yujiri, Tadahiko Igarashi, Arinobu Tojo, Seiichi Shimizu, Satoru Hara, Atsushi Shinagawa, Keiji Sugimoto, Hisayuki Yokoyama
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 9, Iss 11, Pp 3742-3751 (2020)
Cancer Medicine, Vol 9, Iss 11, Pp 3742-3751 (2020)
For patients who have chronic myeloid leukemia (CML), one of the primary treatment options is administration of nilotinib 300 mg twice daily (BID). In previous studies which compared outcomes associated with nilotinib or imatinib treatment, nilotinib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e1a135fb41bbe0942d5a4e73ad7f047a
https://doi.org/10.1002/cam4.3034
https://doi.org/10.1002/cam4.3034
Autor:
Kazuyuki Aihara, Kazuhisa Fujikawa, Mayuko Tsuda, Satoru Hara, Mitsuhito Hirano, Arinobu Tojo, Tadahiko Igarashi, Junichi Hisatake, Takeaki Sugawara, Shinji Nakaoka, Atsushi Shinagawa, Kaichi Nishiwaki, Toshiaki Yujiri, Shigehisa Tamaki, Hisashi Wakita, Kai Morino, Masashi Kajita, Kei-ji Sugimoto, Yuji Okamoto, Seiichi Shimizu, Hisayuki Yokoyama
Publikováno v:
NPJ systems biology and applications. 8(1)
Chronic myeloid leukemia (CML) is a myeloproliferative disorder caused by the BCR-ABL1 tyrosine kinase1,2. ABL1-selective tyrosine kinase inhibitors (TKIs) including nilotinib have dramatically improved the prognosis of patients with CML3–7. The ul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::508b55c7f60f1fc460861d429c8a2dbb
https://pubmed.ncbi.nlm.nih.gov/36229495
https://pubmed.ncbi.nlm.nih.gov/36229495
Autor:
Kyoya Kumagai, Tsutomu Takahashi, Moritaka Gotoh, Yasuhito Nanya, Toshihiro Miyamoto, Mototsugu Shimokawa, Yasushi Takamatsu, Itaru Matsumura, Naoki Kurita, Kiyohiko Hatake, Isao Yoshida, Keisuke Aiba, Kenichi Ishizawa, Noriko Usui, Kazuo Tamura, Tadahiko Igarashi
Publikováno v:
In Vivo. 33:1355-1362
Background/aim Although neurokinin-1 receptor antagonists are approved chemotherapy drugs in Japan, no nationwide surveys have been performed to validate chemotherapy-induced nausea and vomiting (CINV) guidelines in clinical practice. This study eval
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a6345c8af8e9394ddbf6a48280eb61ca
https://doi.org/10.21873/invivo.11611
https://doi.org/10.21873/invivo.11611